Johnson & Johnson secures EU approval for Rybrevant and Lazcluze combo as first-line NSCLC treatment, based on Phase III MARIPOSA trial data. The approval follows FDA setbacks for a subcutaneous ...
"A dynamic and versatile pharmaceutical company with regional horizons in Latin America." "Axon Pharma is an independent multinational pharmaceutical company built on high-standards science and ...